RxDoctor Payments Data

Jennifer Cook, MD

Advanced Heart Failure and Transplant Cardiology · Little Rock, ARNPI 1619075363

Payments from drug & device makers

$84,908in general payments, 2019–2025

Across 72 payments — averaging $1179.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procyrion, Inc.$52K
  • Actelion Pharmaceuticals, Ltd$22K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Amgen$3K
  • Abbott$2K
  • Abiomed$422
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$57213%
  • Food & beverage$3,68587%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$34,539
Medicare patients
372
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan85$120,813
JardianceEmpagliflozin53$63,813
EliquisApixaban31$40,878
FarxigaDapagliflozin Propanediol24$22,544
Sirolimus14$10,864
Eplerenone42$3,611
Potassium Chloride20$1,353
Torsemide64$1,286
Metoprolol Succinate85$1,032
Spironolactone100$900
Atorvastatin Calcium57$556
Rosuvastatin Calcium39$538
Carvedilol77$533
Tacrolimus12$443
Valsartan35$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$63,81353 claims
PfizerEliquis$14$40,87831 claims
AstraZenecaFarxiga$34$22,54424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Little Rock

Where these figures come from

Is this you, or does something look wrong? →